Susan Sergeant1,2, Brian Hallmark3, Rasika A Mathias2,4, Tammy L Mustin2,5, Priscilla Ivester2,5, Maggie L Bohannon2,5, Ingo Ruczinski2,6, Laurel Johnstone3, Michael C Seeds2,7, Floyd H Chilton2,3. 1. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. 2. Center for Botanical Lipids and Inflammatory Disease Prevention, Wake Forest School of Medicine,Winston-Salem, NC, USA. 3. BIO5 Institute, University of Arizona, Tucson, AZ, USA. 4. Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Physiology/Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, USA. 6. Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, MD, USA. 7. Department of Internal Medicine, Section on Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
BACKGROUND: Unexplained heterogeneity in clinical trials has resulted in questions regarding the effectiveness of ɣ-linolenic acid (GLA)-containing botanical oil supplements. This heterogeneity may be explained by genetic variation within the fatty acid desaturase (FADS) gene cluster that is associated with circulating and tissue concentrations of arachidonic acid (ARA) and dihomo-ɣ-linolenic acid (DGLA), both of which may be synthesized from GLA and result in proinflammatory and anti-inflammatory metabolites, respectively. OBJECTIVES: The objective of this study was to prospectively compare the capacity of a non-Hispanic white cohort, stratified by FADS genotype at the key single-nucleotide polymorphism (SNP) rs174537, to metabolize 18-carbon omega-6 (n-6) PUFAs in borage oil (BO) and soybean oil (SO) to GLA, DGLA, and ARA. METHODS:Healthy adults (n = 64) participated in a randomized, double-blind, crossover intervention. Individuals received encapsulated BO (Borago officinalis L.; 37% LA and 23% GLA) or SO [Glycine max (L.) Merr.; 50% LA and 0% GLA] for 4 wk, followed by an 8-wk washout period, before consuming the opposite oil for 4 wk. Serum lipids and markers of inflammation (C-reactive protein) were assessed for both oil types at baseline and during weeks 2 and 4 of the intervention. RESULTS: SO supplementation failed to alter circulating concentrations of any n-6 long-chain PUFAs. In contrast, a modest daily dose of BO elevated serum concentrations of GLA and DGLA in an rs174537 genotype-dependent manner. In particular, DGLA increased by 57% (95% CI: 0.38, 0.79) in GG genotype individuals, but by 141% (95% CI: 1.03, 2.85) in TT individuals. For ARA, baseline concentrations varied substantially by genotype and increased modestly with BO supplementation, suggesting a key role for FADS variation in the balance of DGLA and ARA. CONCLUSIONS: The results of this study clearly suggest that personalized and population-based approaches considering FADS genetic variation may be necessary to optimize the design of future clinical studies with GLA-containing oils. This trial was registered at clinicaltrials.gov as NCT02337231.
RCT Entities:
BACKGROUND: Unexplained heterogeneity in clinical trials has resulted in questions regarding the effectiveness of ɣ-linolenic acid (GLA)-containing botanical oil supplements. This heterogeneity may be explained by genetic variation within the fatty acid desaturase (FADS) gene cluster that is associated with circulating and tissue concentrations of arachidonic acid (ARA) and dihomo-ɣ-linolenic acid (DGLA), both of which may be synthesized from GLA and result in proinflammatory and anti-inflammatory metabolites, respectively. OBJECTIVES: The objective of this study was to prospectively compare the capacity of a non-Hispanic white cohort, stratified by FADS genotype at the key single-nucleotide polymorphism (SNP) rs174537, to metabolize 18-carbonomega-6 (n-6) PUFAs in borage oil (BO) and soybeanoil (SO) to GLA, DGLA, and ARA. METHODS: Healthy adults (n = 64) participated in a randomized, double-blind, crossover intervention. Individuals received encapsulated BO (Borago officinalis L.; 37% LA and 23% GLA) or SO [Glycine max (L.) Merr.; 50% LA and 0% GLA] for 4 wk, followed by an 8-wk washout period, before consuming the opposite oil for 4 wk. Serum lipids and markers of inflammation (C-reactive protein) were assessed for both oil types at baseline and during weeks 2 and 4 of the intervention. RESULTS: SO supplementation failed to alter circulating concentrations of any n-6 long-chain PUFAs. In contrast, a modest daily dose of BO elevated serum concentrations of GLA and DGLA in an rs174537 genotype-dependent manner. In particular, DGLA increased by 57% (95% CI: 0.38, 0.79) in GG genotype individuals, but by 141% (95% CI: 1.03, 2.85) in TT individuals. For ARA, baseline concentrations varied substantially by genotype and increased modestly with BO supplementation, suggesting a key role for FADS variation in the balance of DGLA and ARA. CONCLUSIONS: The results of this study clearly suggest that personalized and population-based approaches considering FADS genetic variation may be necessary to optimize the design of future clinical studies with GLA-containing oils. This trial was registered at clinicaltrials.gov as NCT02337231.
Authors: Susan Sergeant; Christina E Hugenschmidt; Megan E Rudock; Julie T Ziegler; Priscilla Ivester; Hannah C Ainsworth; Dhananjay Vaidya; L Douglas Case; Carl D Langefeld; Barry I Freedman; Donald W Bowden; Rasika A Mathias; Floyd H Chilton Journal: Br J Nutr Date: 2011-07-04 Impact factor: 3.718
Authors: Matteo Fumagalli; Ida Moltke; Niels Grarup; Fernando Racimo; Peter Bjerregaard; Marit E Jørgensen; Thorfinn S Korneliussen; Pascale Gerbault; Line Skotte; Allan Linneberg; Cramer Christensen; Ivan Brandslund; Torben Jørgensen; Emilia Huerta-Sánchez; Erik B Schmidt; Oluf Pedersen; Torben Hansen; Anders Albrechtsen; Rasmus Nielsen Journal: Science Date: 2015-09-18 Impact factor: 47.728
Authors: Austin G Hester; Robert C Murphy; Charis J Uhlson; Priscilla Ivester; Tammy C Lee; Susan Sergeant; Leslie R Miller; Timothy D Howard; Rasika A Mathias; Floyd H Chilton Journal: J Biol Chem Date: 2014-06-24 Impact factor: 5.157
Authors: Floyd H Chilton; Rahul Dutta; Lindsay M Reynolds; Susan Sergeant; Rasika A Mathias; Michael C Seeds Journal: Nutrients Date: 2017-10-25 Impact factor: 5.717
Authors: Joel T M Bamford; Sujoy Ray; Alfred Musekiwa; Christel van Gool; Rosemary Humphreys; Edzard Ernst Journal: Cochrane Database Syst Rev Date: 2013-04-30
Authors: Veronica A Mullins; William Bresette; Laurel Johnstone; Brian Hallmark; Floyd H Chilton Journal: Nutrients Date: 2020-10-13 Impact factor: 5.717
Authors: Neil K Huang; Petra Bůžková; Nirupa R Matthan; Luc Djoussé; Calvin H Hirsch; Jorge R Kizer; W T Longstreth; Kenneth J Mukamal; Alice H Lichtenstein Journal: J Am Heart Assoc Date: 2021-03-08 Impact factor: 5.501
Authors: Floyd H Chilton; Ani Manichaikul; Chaojie Yang; Timothy D O'Connor; Laurel M Johnstone; Sarah Blomquist; Susan M Schembre; Susan Sergeant; Manja Zec; Michael Y Tsai; Stephen S Rich; Susan J Bridgewater; Rasika A Mathias; Brian Hallmark Journal: Front Nutr Date: 2022-02-08
Authors: Topi Meuronen; Maria A Lankinen; Olli Kärkkäinen; Markku Laakso; Jussi Pihlajamäki; Kati Hanhineva; Ursula Schwab Journal: Eur J Nutr Date: 2021-10-31 Impact factor: 5.614
Authors: Beverly Dosso; Charlotte Mae K Waits; Kelli N Simms; Susan Sergeant; D Clark Files; Timothy D Howard; Carl D Langefeld; Floyd H Chilton; Elaheh Rahbar Journal: Curr Dev Nutr Date: 2020-09-14
Authors: L Madison Kirk; Charlotte Mae K Waits; Alexander C Bashore; Beverly Dosso; Allison K Meyers; Antonio C Renaldo; Thomas J DePalma; Kelli N Simms; Nathaniel Hauser; Chia-Chi Chuang Key; Charles E McCall; John S Parks; Susan Sergeant; Carl D Langefeld; Aleksander Skardal; Elaheh Rahbar Journal: PLoS One Date: 2022-01-20 Impact factor: 3.752